Consider drug efficacy before first-in-human trials

Jonathan Kimmelman () and Carole Federico
Additional contact information
Jonathan Kimmelman: Jonathan Kimmelman is associate professor of biomedical ethics at McGill University, Montreal, Canada.
Carole Federico: Carole Federico is a PhD candidate at McGill University, Montreal, Canada.

Nature, 2017, vol. 542, issue 7639, 25-27

Abstract: Ethical review boards must focus on clinical promise as well as safety to hold the first tests of drugs in humans to a higher standard, say Jonathan Kimmelman and Carole Federico.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/542025a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:542:y:2017:i:7639:d:10.1038_542025a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/542025a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().